General versus subpopulation values in bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patients

American Journal of Health-System Pharmacy

Volumn 54, Issue 5, 1997, Pages 541-544

  Radomski, Kristine M ^a,b,c   Davis, George A ^d   Chandler, Mary H H ^e,f  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c University of Kentucky   (United States)

^d ASHP Foundation   (United States)

^e Postgraduate Year One Pharmacy Residency Program   (United Kingdom)

^f UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Aminoglycosides; Blood levels; Calculations; Computers; Drugs, body distribution; Excretion; Gentamicin; Hematologic diseases; Methodology; Neoplasms; Pharmacokinetics; Tobramycin

Indexed keywords

AMINOGLYCOSIDE; GENTAMICIN; TOBRAMYCIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0031048237     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.5.541     Document Type: Article

References (28)

1. Barza M, Lauermann M. Why monitor serum levels of gentamicin. Clin Pharmacokinet. 1978; 3:202-15.
2. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984; 77:657-62.
3. Segal JL, Gray DR, Gordon SK. Pharmacokinetics of gentamicin in patients with spinal cord injury. Clin Pharm. 1984; 3:418-20.
4. Gardner DK, Schneider PJ, Gentamicin dosage requirement in post-parturn patients. Clin Pharm. 1984; 3:416-8.
5. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993; 21:172-3.
6. Manny RP, Hutson PR. Aminoglycoside volume of distribution in hematology/oncology patients. Clin Pharm. 1986; 5:629-32.
7. Higa GM, Murray WE. Alterations in aminoglycoside pharmacokinetics in patients with cancer. Clin Pharm. 1987; 6:963-6.
8. Kaojarern S, Maoleekoonpairoj S, Atichartakarn V. Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob Agents Chemother. 1989; 33:1406-8.
9. Davis RL, Lehmann D, Stidley CA et al. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob Agents Chemother. 1991; 35:944-7.
10. Zeitany RG, El Saghir NS, Santhosh-Kumar R et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother. 1990; 34:702-8.
11. Sheiner LB, Beal S, Rosenberg B et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979; 26:294-305.
12. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet. 1992; 22:447-67.
13. Chandler MHH. Bayesian forecasting: theoretical and practical considerations in clinical pharmacokinetics. Clin Trends Hosp Pharm. 1990; 4(2):17-21.
14. McClellan SD, Farringer JA. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as the internal estimates. Ther Drug Monit. 1989; 11:431-6.
15. Abbott Laboratories Diagnostics Division. TDxFLx TDx assays manual. Abbott Park, IL: Abbott Laboratories; 1994:113:1-5.
16. Ibid. P110:1-5.
17. Mosteller RD. Simplified calculations of body-surface area. N Engl J Med. 1987; 317:1098. Letter.
18. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974; 8:650-5.
19. Blouin RA, Chandler MHH. Special pharmacokinetic considerations in the obese. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics; 1992:11.1-11.20.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
21. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976; 4:183-95.
22. Abbott Laboratories Diagnostics Division. Abbottbase pharmacokinetic systems operations manual. Abbott Park, IL: Abbott Laboratories; 1993:102:4.4.7.
23. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9:503-12.
24. Leader WG, Tsubaki T, Chandler MHH. Creatinine clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm. 1994; 51:2125-30.
25. Carlstedt BC, Uaamnuichai M, Day RB et al. Aminoglycoside dosing in pediatric patients. Ther Drug Monit. 1989; 11:38-43.
26. Lanao JM, Berrocal A, Calvo MV et al. Population pharmacokinetic study of gentamicin and a Bayesian approach in patients with renal impairment. J Clin Pharm Ther. 1989; 14:213-23.
27. Rosell-Rovira ML, Pou-Clave L, Garcia-Beltran L et al. Gentamicin pharmacokinetics in adults with bacterial endocarditis. Am J Hosp Pharm. 1994; 51:1429-32.
28. Kosirog JL, Rospond RM, Destache C et al. Aminoglycoside forecasting in neutropenic patients with cancer. Clin Pharmacokinet 1993; 24:79-87.